ScholarIQanswers from OpenAlex & ORCID
Elgene Lim
ResearcherPublications, citations & collaboration network
Elgene Lim is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Elgene Lim have?
ScholarIQindexed works
Elgene Lim has 363 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Elgene Lim have?
ScholarIQcitation count
Elgene Lim has 16,604 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Elgene Lim?
ScholarIQh-index
Elgene Lim has an h-index of 54 in OpenAlex.
What is the i10-index of Elgene Lim?
ScholarIQi10-index
Elgene Lim has an i10-index of 120 in OpenAlex.
What is the ORCID of Elgene Lim?
ScholarIQorcid
The ORCID for Elgene Lim is on the source record.
What is the OpenAlex record for Elgene Lim?
ScholarIQopenalex
The OpenAlex for Elgene Lim is on the source record.
What are the most-cited papers on Elgene Lim?
ScholarIQmost cited works
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruíz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Wu Cai, Changan Chu, Anton Egorov, Ian E. Krop